These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32197944)

  • 1. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.
    Vranic S; Stafford P; Palazzo J; Skenderi F; Swensen J; Xiu J; Spetzler D; Gatalica Z
    Clin Breast Cancer; 2020 Aug; 20(4):326-331.e1. PubMed ID: 32197944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
    Joneja U; Vranic S; Swensen J; Feldman R; Chen W; Kimbrough J; Xiao N; Reddy S; Palazzo J; Gatalica Z
    J Clin Pathol; 2017 Mar; 70(3):255-259. PubMed ID: 27531819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
    Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
    Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
    Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
    Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
    Vranic S; Senarathne W; Stafford P; Poorman K; Pockaj BA; Gatalica Z
    Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):661-668. PubMed ID: 31517642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
    Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
    Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
    Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
    Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].
    Weigelt B; Ng CK; Shen R; Popova T; Schizas M; Natrajan R; Mariani O; Stern MH; Norton L; Vincent-Salomon A; Reis-Filho JS
    Mod Pathol; 2015 Mar; 28(3):340-51. PubMed ID: 25412848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
    Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
    Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
    McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
    Cimic A; Vranic S; Arguello D; Contreras E; Gatalica Z; Swensen J
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):299-304. PubMed ID: 33208671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
    Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
    Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.
    Krings G; Chen YY
    Mod Pathol; 2018 Nov; 31(11):1661-1674. PubMed ID: 29946183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.